Wednesday, 20 Nov 2019

You are here

Enbrel Patent Battle Won by Amgen

The ugly, legal, financial underbelly of US biosimilar drug development showed up in court last Friday, when a U.S. judge upheld two of Amgen's patents for Enbrel, thwarting a legal challenge by Novartis/Sandoz over its etanercept-szzs biosimilar, Erelzi. 

Sandoz won FDA approval for their etanercept biosimilar in 2016, but has not been able to market Erelzi because of Amgen’s extended patent protection (till 2029).

Although Enbrel sales have dropped in recent years, it is still a blockbuster biologic with U.S. sales of $4.8 billion last year.  

U.S. District Judge Claire Cecchi in Newark, New Jersey, rejected arguments by Novartis’ Sandoz unit that the patents covering Enbrel’s active ingredient until 2029 should not have been granted because their concepts were already contained in previous patents.

Novartis said it would appeal the ruling to the United States Court of Appeals for the Federal Circuit. 

“Sandoz respectfully disagrees with the Court’s ruling, which prevents us from launching an additional treatment option for patients with autoimmune and inflammatory diseases,” said Carol Lynch, President of Sandoz US and Head of North America. “Valid intellectual property should be respected, however, we continue to consider the patents in this case to be invalid. Amgen asserted two patents that it obtained from Roche, in what we believe is an attempt to extend its US compound patent protection for etanercept to 2029. We will appeal this decision, and look forward to presenting our case to the Federal Circuit and bringing Erelzi to US patients as soon as possible.”

While many U.S. regulators and politicians have called for the adoption and wider use of “biosimilar” versions of expensive biologic drugs, patent litigation and negotiations between companies have stalled the use of newer biosimilar versions of adalimumab and etanercept.  Only the infliximab biosimilars are currently marketed and in use. 

Amgen is also suing Samsung Bioepis over its Enbrel biosimilar. That litigation remains under way, an Amgen spokeswoman said on Friday. Officials at Samsung Bioepis did not immediately respond to a request for comment.

The economics of biologic drug use is such that they account for nearly 40% of U.S. prescription drug spending, and 70% of the growth in drug spending between 2010 and 2015.

Biosimilar

Reference

Pharma

Generic -suffix

Approved

Inflectra

Remicade

Celltrion

infliximab-dyyb

April 2016

Erelzi

Enbrel

Sandoz

etanercept-szzs

August 2016

Amjevita

Humira

Amgen

adalimumab-atto

Sept 2016

Renflexis

Remicade

Samsung

infliximab-abda

May  2017

Cyltezo

Humira

Boehringer

adalimumab-adbm

August 2017

Ixifi

Remicade

Pfizer

infliximab-abda

December 2017

Hyrimoz

Humira

Sandoz

adalimumab-adaz

October 2018

Eticovo

Enbrel

Samsung

etanercept-szzs

April 2019

Hadlima 

Humira

Samsung

adalimumab-bwwd

July 2019

 

 

Add new comment

More Like This

Psoriasis Risk Increased with TNF Inhibitors in Juveniles

Children with inflammatory diseases who were treated with tumor necrosis factor (TNF) inhibitors had a higher rate of incident psoriasis than those not exposed to these biologics, a single-center retrospective study found.

The Shame Behind Adalimumab Biosimilars

JAMA has an article this week on the shift from biologic drugs to less expensive therapeutic biosimilar agents. The impact of biosimilars can be easily represented by the shift from adalimuamb - a biologic with nearly $19 billion in sales in 2018 - to any one of the four FDA approved biosimilars for adalimumab (see the daily download for slides on new adalimumab and other biosimilars).

Pain Persists Despite TNF Inhibitor Use

Control of pain in patients with rheumatoid arthritis (RA) often focuses on control of inflammation as a means to better control pain. However, a new claims data study shows that while anti-tumor necrosis factor inhibitor (TNFi) may lower the use of opioids, the reduction is nominal, suggesting that a substantial amount of pain is not adequately addressed by TNFi - a potent anti-inflammatory approach.

Adalimumab and Pregnancy Outcomes

A prospective study of birth outcomes to mothers exposed to adalimumab (ADA) between 2004 and 2016 was conducted by Organization of Teratology Information Specialists (OTIS) Research Center at the University of California San Diego, and showed that ADA exposure was not associated with an increased risk for any of the adverse outcomes examined.

TNF Inhibitor and Biologic Induced Psoriasis

Analysis of RA patients in the German biologics register, RABBIT, shows an increased risk of psoriasis with TNF inhibitor (TNFi) compared to csDMARDs and other non-TNFi biologics. 

Among RABBIT RA patients without (n = 14,525) or with a history of psoriasis (n = 375) they assessed the risk of incident psoriasis or flare according to what biologic or csDMARD taken.